A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer

Lung Cancer. 2004 Mar;43(3):329-33. doi: 10.1016/j.lungcan.2003.08.031.


Purpose: To evaluate the efficacy and toxicity of the combination of gemcitabine and docetaxel in pretreated patients with small-cell lung cancer (SCLC).

Patients and methods: Twenty-two pretreated patients (median age 61 years, PS: 0-1 in 77% and 2 in 23%) with limited or extensive stage disease were treated with gemcitabine 1000 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8, every 21 days. Fifteen (68%) of the 22 patients had received two prior regimens and fourteen (64%) were refractory to front-line chemotherapy.

Results: All patients were evaluable for efficacy analysis. No complete or partial responses were observed. Disease stabilization was obtained in one (5%) patient. The median survival was 14 weeks and the six-month survival rate was 28%. WHO grade 2 and 3 toxicities were infrequent and easily manageable.

Conclusion: The combination of gemcitabine and docetaxel was inactive as salvage treatment in this poor prognosis group of patients with SCLC.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Docetaxel
  • Female
  • Gemcitabine
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Salvage Therapy
  • Taxoids / administration & dosage


  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Gemcitabine